YOLFTbeta
Trellus Health plc

Trellus Health plc

TRLS · LSE · Healthcare / Health Information Services

0.12GBX+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.12
Open0.12
Day Range0.12 – 0.12
52-Week Range0.04 – 1.75
Volume0
Market Cap516.14K
P/E (TTM)0.00
Forward P/E0.00
EPS-0.04
Dividend Yield0.00%
Beta2.53
50-Day Avg0.017
200-Day Avg0.2227

About

Trellus Health plc provides digital chronic condition management solutions for employers and health plans. The company offers GRITT resilience-based methodology; and TrellusElevate, a HIPAA-compliant technology platform for remote telemedicine care. Its platform provides support for managing inflammatory bowel disease, including Crohn's Disease and ulcerative colitis. The company was incorporated in 2020 and is headquartered in White Plains, New York.

Company Details

  • SectorHealthcare
  • IndustryHealth Information Services
  • CEODr. Marla Cindy Dubinsky M.D.
  • Employees18
  • Headquarters44 South Broadway, White Plains, NY, United States, 10601, UK
  • Websitehttps://www.trellushealth.com

Leadership

  • Dr. Marla Cindy Dubinsky M.D.Co-Founder, CEO & Director
  • Dr. Laurie Keefer Ph.D.Co-Founder & Chair of Scientific Advisory Board
  • Ms. Joy Bessenger B.A.Chief Financial Officer
  • Ms. Kathleen WilliamsChief Operating & Innovation Officer
  • Ms. Amy MurphyDirector of Human Resources
  • Leah Conley M.B.A.Head of Global Market Access - Travere Therapeutics & Member of Scientific Advisory Board

Financials

Income Statement

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-31
Total Revenue-25.00K18.00K19.00K114.00K
Growth (%)---28.00%+5.56%+500.00%
Cost of Revenue-0000
Gross Profit-25.00K18.00K19.00K114.00K
Gross Margin-100.00%100.00%100.00%100.00%
Operating Expense-5.93M8.83M6.82M8.14M
Operating Income-1.52M-5.90M-8.81M-6.80M-8.03M
Operating Margin--23608.00%-48944.44%-35805.26%-7041.23%
EBITDA-1.52M-5.87M-8.27M-6.50M-7.16M
EBITDA Margin--23480.00%-45966.67%-34194.74%-6281.58%
Net Income-1.52M-5.90M-8.81M-6.34M-7.78M
Net Income Margin--23608.00%-48944.44%-33363.16%-6826.32%
R&D-22.00K593.00K--
R&D as % of Total Revenue-88.00%3294.44%--
Interest Expense000--
Interest Expense % of Total Revenue-0.00%0.00%--

Balance Sheet

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-31
Total Assets4.37M36.80M25.91M20.29M12.14M
Total Liabilities122.00K1.52M822.00K786.00K371.00K
Total Equity4.25M35.27M25.09M19.50M11.77M
Cash3.68M31.98M19.09M12.17M4.34M
Net Debt-3.68M-31.98M-19.09M-12.17M-4.34M

Cash Flow

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-31
Operating Cash Flow-1.30M-4.77M-8.62M-5.27M-7.32M
Investing Cash Flow-1.35M-3.72M-2.91M-2.35M-540.00K
Financing Cash Flow10.02M38.52M---
Capital Expenditure24.00K3.72M2.91M2.35M540.00K
Free Cash Flow-1.32M-8.49M-11.53M-7.63M-7.86M
FCF to OCF101.85%177.98%133.74%144.58%107.38%

Key Statistics & Ratios

Market Cap516.14K
Enterprise Value-659.08K
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.44
Price / Book0.08
EPS-0.04
Book Value0.0408
Revenue (TTM)359.00K
Gross Profit (TTM)359.00K
EBITDA-6.93M
Profit Margin0.00%
Operating Margin-1022.03%
Return on Equity-56.65%
Return on Assets-34.37%
Shares Outstanding430.12M
Shares Float140.66M
Beta2.53
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%